Improving the immunogenicity of HIV-1 envelope trimer vaccines

por Sanders, Rogier W
Publicado 2011

HIV takes double hit before entry

por Sanders, Rogier W
Publicado 2012

Structure‐guided envelope trimer design in HIV‐1 vaccine development: a narrative review

por Derking, Ronald, Sanders, Rogier W.
Publicado 2021

Native‐like Env trimers as a platform for HIV‐1 vaccine design

por Sanders, Rogier W., Moore, John P.
Publicado 2017

Virus vaccines: proteins prefer prolines

por Sanders, Rogier W., Moore, John P.
Publicado 2021

Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms

por Brouwer, Philip J.M., Sanders, Rogier W.
Publicado 2019

Pandemic moves and countermoves: vaccines and viral variants

por Sanders, Rogier W, de Jong, Menno D
Publicado 2021

Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies

por Torrents de la Peña, Alba, Sanders, Rogier W.
Publicado 2018

Stabilized HIV-1 envelope glycoprotein trimers for vaccine use

por Medina-Ramírez, Max, Sanders, Rogier W., Sattentau, Quentin J.
Publicado 2017

Enhanced Immunogenicity of HIV-1 Envelope gp140 Proteins Fused to APRIL

por Isik, Gözde, Sliepen, Kwinten, van Montfort, Thijs, Sanders, Rogier W.
Publicado 2014

Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry

por Berro, Reem, Sanders, Rogier W., Lu, Min, Klasse, Per J., Moore, John P.
Publicado 2009

HIV-1 envelope characteristics that coincide with the development of cross-reactive neutralizing activity in HIV-1 infected patients

por van den Kerkhof, Tom, van Gils, Marit, Euler, Zelda, Verwer, Naomi, Sanders, Rogier, Schuitemaker, Hanneke
Publicado 2011

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41

por Sanders, Rogier W, Dankers, Martijn M, Busser, Els, Caffrey, Michael, Moore, John P, Berkhout, Ben
Publicado 2004

Chimeric HIV-1 Envelope Glycoproteins with Potent Intrinsic Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Activity*

por Isik, Gözde, van Montfort, Thijs, Boot, Maikel, Cobos Jiménez, Viviana, Kootstra, Neeltje A., Sanders, Rogier W.
Publicado 2013

HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry

por Eggink, Dirk, Bontjer, Ilja, de Taeye, Steven W., Langedijk, Johannes P. M., Berkhout, Ben, Sanders, Rogier W.
Publicado 2019

Correction: HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry

por Eggink, Dirk, Bontjer, Ilja, de Taeye, Steven W., Langedijk, Johannes P.M., Berkhout, Ben, Sanders, Rogier W.
Publicado 2022

Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer

por Sliepen, Kwinten, van Montfort, Thijs, Ozorowski, Gabriel, Pritchard, Laura K., Crispin, Max, Ward, Andrew B., Sanders, Rogier W.
Publicado 2015

Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide

por Kumar, Sonu, Sarkar, Anita, Pugach, Pavel, Sanders, Rogier W., Moore, John P., Ward, Andrew B., Wilson, Ian A.
Publicado 2019

Stable HIV-1 envelope glycoprotein immune complexes as vaccine immunogens

por van Montfort, Thijs, Melchers, Mark, van Capel, Tony MM, de Jong, Ester C, Paxton, William A, Sanders, Rogier W
Publicado 2011

Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env

por Guttman, Miklos, Cupo, Albert, Julien, Jean-Philippe, Sanders, Rogier W., Wilson, Ian A., Moore, John P., Lee, Kelly K.
Publicado 2015